Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients (Q33400076)

26 July 2017

title

Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients (English)

1 reference

26 July 2017

1 reference

Françoise Kraeber-Bodéré

14

Françoise Kraeber-Bodéré

0 references

Alain Faivre-Chauvet

6

Alain Faivre-Chauvet

0 references

Stéphane Supiot

Stéphane Supiot

3

0 references

Jacques Barbet

Jacques Barbet

10

0 references

Philippe Moreau

12

Philippe Moreau

1 reference

26 July 2017

15

Michel Cherel

1 reference

26 July 2017

Caroline Rousseau

1

1 reference

26 July 2017

Ludovic Ferrer

2

1 reference

26 July 2017

Manuel Bardiès

4

1 reference

26 July 2017

François Davodeau

5

1 reference

26 July 2017

Pierre Baumgartner

7

1 reference

26 July 2017

John Wijdenes

8

1 reference

26 July 2017

Marie Lacombe

9

1 reference

26 July 2017

Thierry Guillaume

11

1 reference

26 July 2017

Jean Luc Harousseau

13

1 reference

26 July 2017

publication date

3 March 2012

1 reference

26 July 2017

1 reference

26 July 2017

volume

33

1 reference

26 July 2017

issue

3

1 reference

26 July 2017

page(s)

679-688

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0362-Y

26 July 2017

1 reference

Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0362-Y

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0362-Y

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0362-Y

Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0362-Y

Bone marrow stroma confers resistance to Apo2 ligand/TRAIL in multiple myeloma in part by regulating c-FLIP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0362-Y

Syndecan-1: a dynamic regulator of the myeloma microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0362-Y

Cell surface proteoglycan binds mouse mammary epithelial cells to fibronectin and behaves as a receptor for interstitial matrix

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0362-Y

The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0362-Y

Efficacy and toxicity of plasma-cell-reactive monoclonal antibodies B-B2 and B-B4 and their immunotoxins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0362-Y

Interleukin-6 is a growth factor for nonmalignant human plasmablasts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0362-Y

Characterization of clonogenic multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0362-Y

Identification of translocation products but not K-RAS mutations in memory B cells from patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0362-Y

Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0362-Y

Soluble syndecan-1 promotes growth of myeloma tumors in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0362-Y

New antibody conjugates in cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0362-Y

User-guided 3D active contour segmentation of anatomical structures: significantly improved efficiency and reliability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0362-Y

Three methods assessing red marrow dosimetry in lymphoma patients treated with radioimmunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0362-Y

Physical models and dose factors for use in internal dose assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0362-Y

F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0362-Y

A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0362-Y

Comparison of the biologic effects of MA5 and B-B4 monoclonal antibody labeled with iodine-131 and bismuth-213 on multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0362-Y

Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0362-Y

Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0362-Y

Organ involvement and phenotypic adhesion profile of 5T2 and 5T33 myeloma cells in the C57BL/KaLwRij mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0362-Y

A method to correct for radioactivity in large vessels that overlap the spine in imaging-based marrow dosimetry of lumbar vertebrae.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0362-Y

Establishing a clinically meaningful predictive model of hematologic toxicity in nonmyeloablative targeted radiotherapy: practical aspects and limitations of red marrow dosimetry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0362-Y

Multiple myeloma: monoclonal antibodies-based immunotherapeutic strategies and targeted radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0362-Y

Radioimmunotherapy with alpha-particle emitting radioimmunoconjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0362-Y

Cancer radioimmunotherapy with alpha-emitting nuclides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0362-Y

Target apex-seeking in factor analysis of medical image sequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0362-Y

Radioimmunotherapy with alpha-emitting nuclides

21 January 2018

1 reference

12 December 2020

Validation of 213Bi-alpha radioimmunotherapy for multiple myeloma

1 reference

12 December 2020

A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1

1 reference

12 December 2020

Red marrow dosimetry for radiolabeled antibodies that bind to marrow, bone, or blood components

1 reference

12 December 2020

Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen

1 reference

12 December 2020

Serum syndecan-1: a new independent prognostic marker in multiple myeloma

1 reference

12 December 2020

The peripheral CD138+ population but not the CD138− population contains myeloma clonogenic cells in plasma cell leukaemia patients

1 reference

12 December 2020

Dosimetry in patients with B-cell lymphoma treated with [(90)Y]ibritumomab tiuxetan or [(131)I]tositumomab

1 reference

12 December 2020

Estimates of red marrow dose by sacral scintigraphy in radioimmunotherapy patients having non-Hodgkin's lymphoma and diffuse bone marrow uptake

1 reference

12 December 2020

High Frequency of Bone/Bone Marrow Involvement in Advanced Medullary Thyroid Cancer

1 reference

12 December 2020

1 reference

12 December 2020

A practical method for position-dependent Compton-scatter correction in single photon emission CT

1 reference

12 December 2020

Molecular and cellular mechanisms of syndecans in tissue injury and inflammation

1 reference

12 December 2020

Comparative targeting of human colon-carcinoma multicell spheroids using one- and two-step (bispecific antibody) techniques

1 reference

12 December 2020

Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial

1 reference

12 December 2020

Imaging for improved prediction of myelotoxicity after radioimmunotherapy

1 reference

12 December 2020

MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates

1 reference

12 December 2020

Unraveling the biology of multiple myeloma disease: cancer stem cells, acquired intracellular changes and interactions with the surrounding micro-environment

1 reference

12 December 2020

10.1007/S13277-012-0362-Y

Identifiers

DOI

1 reference

Dimensions Publication ID

26 July 2017

1003557788

0 references

1 reference